Evolent Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Evolent Health, Inc. on June 22, 2017. The report details the entry into a material definitive agreement regarding an underwritten secondary public offering of the company's Class A common stock.
Key Financial Metrics
The filing does not provide specific financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a secondary offering.
Material Changes and Transaction Details
- Transaction Type: Underwritten secondary public offering of 4,500,000 shares of Class A common stock.
- Sellers: Shares were sold by certain affiliates of TPG Global, LLC, and Ptolemy Capital, LLC (the "Selling Stockholders"). The Company did not sell shares in this offering.
- Underwriters: Goldman Sachs & Co. LLC acted as the representative for the several underwriters.
- Closing Date: The offering closed on June 28, 2017.
- Proceeds: The filing text does not state the offering price per share or the total gross proceeds raised.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It notes that the Underwriting Agreement includes customary representations, warranties, covenants, and indemnification provisions. The offering was made pursuant to a registration statement on Form S-3 declared effective on August 12, 2016.
Investor Verification Checklist
- Verify the offering price per share and total gross proceeds in the related Prospectus Supplement dated June 22, 2017.
- Confirm the specific identities of the Selling Stockholders listed in Schedule 2 of the Underwriting Agreement (Exhibit 1.1).
- Review the full text of the Underwriting Agreement for specific indemnification liabilities and covenants.
- Check subsequent filings for the final closing statement and net proceeds received by the Selling Stockholders.